Reata Pharmaceuticals Inc. Class A (RETA)

The total asset value of Reata Pharmaceuticals Inc. Class A (RETA) stood at $ 508 Mln as on 31-Mar-23

The share price of Reata Pharmaceuticals Inc. Class A (RETA) is $172.36 (NASDAQ) as of 26-Sep-2023 09:30 EST. Reata Pharmaceuticals Inc. Class A (RETA) has given a return of 22.47% in the last 3 years.

Reata Pharmaceuticals Inc. Class A (RETA) has a market capitalisation of $ 3,493 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

The P/B ratio of Reata Pharmaceuticals Inc. Class A (RETA) is 285.94 times as on 02-Jun-2023, a 111.57% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of Reata Pharmaceuticals Inc. Class A (RETA) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Reata Pharmaceuticals Inc. Class A (RETA) and enter the required number of quantities and click on buy to purchase the shares of Reata Pharmaceuticals Inc. Class A (RETA).

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

The CEO & director of Mr. J. Warren Huff. is Reata Pharmaceuticals Inc. Class A (RETA), and CFO & Sr. VP is Mr. Manmeet Singh Soni.

The promoters of Reata Pharmaceuticals Inc. Class A (RETA) have pledged 0% of the total equity as on Mar-23.

Some of the close peers are:

No, TTM profit after tax of Reata Pharmaceuticals Inc. Class A (RETA) was $-354 Mln.